08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Dainippon Sumitomo, Shionogi sales and marketing update

Dainippon and partner Shionogi plan to launch hypertension drug Aimix amlodipine besilate/irbesartan in Japan on Dec. 19. The product is an oral combination of amlodipine besilate, a calcium channel blocker, and irbesartan, an...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Aimix amlodipine besilate/irbesartan regulatory update

Dainippon said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Aimix amlodipine besilate/irbesartan to treat hypertension. Dainippon and Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507, Osaka, Japan) will co-market the product in Japan under...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Dainippon Sumitomo, Shionogi sales and marketing update

Dainippon and Shionogi partnered to co-market Dainippon's amlodipine besylate/irbesartan ( DSP-8153) in Japan. The product is an oral combination of amlodipine besylate, a calcium channel blocker, and irbesartan, an angiotensin II type 1...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Amlodipine besilate/irbesartan regulatory update

Dainippon submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for amlodipine besilate/irbesartan to treat hypertension. The product is an oral combination of amlodipine besilate, a calcium channel blocker, and...